N Barroso1, T G Woodworth1, D E Furst1,2,3, F Guillemin4,5, B J Fautrel6,7, N Borazan1, S Kafaja1, J Brook1, D A Elashoff1, V K Ranganath8. 1. Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California, USA. 2. University of Washington, Seattle, Washington, USA. 3. University of Florence, Florence, Italy. 4. Inserm CIC 1433 Clinical Epidemiology, University Hospital, Nancy, France. 5. Université de Lorraine, EA 4360 APEMAC, Nancy, France. 6. UPMC, GRC08, Pierre Louis Institute of Epidémiology and Public Health, 56 Boulevard Vincent Auriol, Paris, France. 7. Department of Rheumatology, APHP, Pitié-Salpétrière University Hospital, 47-83 Boulevard de l'Hôpital, Paris, France. 8. Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California, USA. vranganath@mednet.ucla.edu.
Abstract
OBJECTIVE: To evaluate use of a British English version of the validated French FLARE-RA questionnaire among American English speaking patients. In addition, to create a culturally adapted American English (AmE) FLARE-RA questionnaire and to examine its attributes of patient-reported RA flare status. METHODS: Using standardized cultural adaptation guidelines, we cognitively debriefed 25 American English speaking rheumatoid arthritis (RA) outpatients and created AmE-FLARE-RA with their input. One hundred three additional RA patients were recruited. Patients completed the Routine Assessment of Patient Index Data 3 (RAPID3), patient global visual analogue scale (VAS), AmE-FLARE-RA, and self-reports of flare. Physician global VAS, physician-assessed flare, swollen and tender joint count (TJC), and clinical disease activity index (CDAI) were documented. AmE-FLARE-RA and disease activity measures were compared between patient-reported and physician-reported flare categories. RESULTS: Patients were female (89%), with mean (SD) age 51.1 (± 15.3) years and mean disease duration (SD) 11.9 (± 10.1) years, with 26% in remission/low disease activity. Total AmE-FLARE-RA scores, RAPID3, CDAI, and patient global VAS were significantly higher for both patient-reported flares and physician-reported flares compared with non-flaring patients by self- or physician report (p < 0.05). Total AmE-FLARE-RA scores correlated significantly with RAPID3 (corr = 0.50, p < 0.0001) and with CDAI (corr = 0.45, p < 0.0001). Across "no flares," "one flare," and "several flare" groups, there was a non-significant increase in AmE-FLARE-RA scores (p = 0.07). CONCLUSION: The British English FLARE-RA was successfully adapted for AmE-speaking RA patients. AmE-FLARE-RA significantly correlated with RAPID3 and CDAI and distinguished between patient-reported and physician-reported flares, making it useful to detect flares in American RA patients.Key Points• The American English FLARE-RA (AmE-FLARE-RA) questionnaire is the result of cognitive debriefing with American RA patients using the British English version of the validated French FLARE-RA and incorporates patient-recommended language modifications..• Patients self-reporting flares had significantly higher AmE-FLARE-RA scores, compared with those without flares at the time of visit. AmE-FLARE-RA scores correlate with RAPID3 and CDAI.• There was a non-statistically significant trend using the AmE-FLARE-RA scores when examining patients with no flare, one flare, or several flares.• AmE-FLARE-RA total scores are uniformly elevated (~ 6.0 on a 0-10 scale), regardless of discordance between patient and MD assessment of flare at time of visit (~ 30%).
OBJECTIVE: To evaluate use of a British English version of the validated French FLARE-RA questionnaire among American English speaking patients. In addition, to create a culturally adapted American English (AmE) FLARE-RA questionnaire and to examine its attributes of patient-reported RA flare status. METHODS: Using standardized cultural adaptation guidelines, we cognitively debriefed 25 American English speaking rheumatoid arthritis (RA) outpatients and created AmE-FLARE-RA with their input. One hundred three additional RA patients were recruited. Patients completed the Routine Assessment of Patient Index Data 3 (RAPID3), patient global visual analogue scale (VAS), AmE-FLARE-RA, and self-reports of flare. Physician global VAS, physician-assessed flare, swollen and tender joint count (TJC), and clinical disease activity index (CDAI) were documented. AmE-FLARE-RA and disease activity measures were compared between patient-reported and physician-reported flare categories. RESULTS:Patients were female (89%), with mean (SD) age 51.1 (± 15.3) years and mean disease duration (SD) 11.9 (± 10.1) years, with 26% in remission/low disease activity. Total AmE-FLARE-RA scores, RAPID3, CDAI, and patient global VAS were significantly higher for both patient-reported flares and physician-reported flares compared with non-flaring patients by self- or physician report (p < 0.05). Total AmE-FLARE-RA scores correlated significantly with RAPID3 (corr = 0.50, p < 0.0001) and with CDAI (corr = 0.45, p < 0.0001). Across "no flares," "one flare," and "several flare" groups, there was a non-significant increase in AmE-FLARE-RA scores (p = 0.07). CONCLUSION: The British English FLARE-RA was successfully adapted for AmE-speaking RA patients. AmE-FLARE-RA significantly correlated with RAPID3 and CDAI and distinguished between patient-reported and physician-reported flares, making it useful to detect flares in American RA patients.Key Points• The American English FLARE-RA (AmE-FLARE-RA) questionnaire is the result of cognitive debriefing with American RA patients using the British English version of the validated French FLARE-RA and incorporates patient-recommended language modifications..• Patients self-reporting flares had significantly higher AmE-FLARE-RA scores, compared with those without flares at the time of visit. AmE-FLARE-RA scores correlate with RAPID3 and CDAI.• There was a non-statistically significant trend using the AmE-FLARE-RA scores when examining patients with no flare, one flare, or several flares.• AmE-FLARE-RA total scores are uniformly elevated (~ 6.0 on a 0-10 scale), regardless of discordance between patient and MD assessment of flare at time of visit (~ 30%).
Authors: Jean-Marie Berthelot; Michel De Bandt; Jacques Morel; Fatima Benatig; Arnaud Constantin; Philippe Gaudin; Xavier Le Loet; Jean-Francis Maillefert; Olivier Meyer; Thao Pham; Alain Saraux; Elisabeth Solau-Gervais; Elisabeth Spitz; Daniel Wendling; Bruno Fautrel; Francis Guillemin Journal: Ann Rheum Dis Date: 2011-11-09 Impact factor: 19.103
Authors: Theresa M Hunter; Natalie N Boytsov; Xiang Zhang; Krista Schroeder; Kaleb Michaud; Andre B Araujo Journal: Rheumatol Int Date: 2017-04-28 Impact factor: 2.631
Authors: Elena Myasoedova; Arun Chandran; Birkan Ilhan; Brittny T Major; C John Michet; Eric L Matteson; Cynthia S Crowson Journal: Ann Rheum Dis Date: 2015-01-30 Impact factor: 19.103
Authors: Zoran Kvrgic; Gladys B Asiedu; Cynthia S Crowson; Jennifer L Ridgeway; John M Davis Journal: Arthritis Care Res (Hoboken) Date: 2018-09-04 Impact factor: 4.794
Authors: Clifton O Bingham; Christoph Pohl; Thasia G Woodworth; Sarah E Hewlett; James E May; Mahboob U Rahman; James P Witter; Daniel E Furst; C Vibeke Strand; Maarten Boers; Rieke E Alten Journal: J Rheumatol Date: 2009-08-14 Impact factor: 4.666
Authors: Stephanie van den Brandt; Astrid Zbinden; Dominique Baeten; Peter M Villiger; Monika Østensen; Frauke Förger Journal: Arthritis Res Ther Date: 2017-03-20 Impact factor: 5.156
Authors: Iris M Markusse; Linda Dirven; Andreas H Gerards; Johannes H L M van Groenendael; H Karel Ronday; Pit J S M Kerstens; Willem F Lems; Tom W J Huizinga; Cornelia F Allaart Journal: Arthritis Res Ther Date: 2015-08-31 Impact factor: 5.156